Home' Australian Pharmacist : Australian Pharmacist April 2015 Contents Australian Pharmacist April 2015 I ©Pharmaceutical Society of Australia Ltd. 85
Make the dream of becoming a doctor a reality, earn
your MD at Oceania University of Medicine.
Attractive fee structure for our Graduate Entry Program.
Over 150 students currently enrolled and over 50
graduates in Australia, New Zealand, Samoa and USA.
Home-based Pre-Clinical Study under top international
medical school scholars, using world leading Pre-Clinical,
24/7 online delivery techniques.
Clinical Rotations can be performed locally, Interstate or
Receive personalised attention from an Academic Advisor.
OUM Graduates are eligible to sit the AMC exam or NZREX.
OCEANIA UNIVERSITY OF MEDICINE
INTERNATIONALLY ACCREDITED For information visit www.oceaniamed.org or 1300 665 343
Applications now open for courses starting in January & July - No age restrictions
BPharm to MD
inno ative approach
is allowing me
to realise my
Pharmacist from Cairns
Class of 2017
It claims Australian patients wait longer
for access to new cancer medicines than
to patients in other parts of the world,
such as the United Kingdom, Canada,
France and Germany.
'Australia is the cancer capital of the world.
We are now living much longer, due to a
variety of reasons, including good public
health policy and extraordinary new
treatments. It is also now likely that half of
all Australians will develop cancer in their
lifetime and one in five will die from it,'
MA CEO, Tim James, said.
In its submission to the Senate Inquiry
into the availability of new, innovative and
specialist cancer drugs in Australia, MA
said the time lag between the Therapeutic
Goods Administration's (TGA) approval
and listing on the Pharmaceutical Benefits
Scheme (PBS) is costing patients' lives.
'We need to challenge how the
Government values new cancer drugs and
better understand how the community
values new treatments for themselves,
and their family members,' Mr James said.
'The benefits of cancer drugs are realised
over time; building on incremental
results to produce other treatments
that target different cancer groups. It's
almost like a slow domino effect, once
one cancer drug shows results it is then
used as a stepping stone to develop
other treatments. So, the value of cancer
medicines grows over time.
'The delay in listing medicines has a
detrimental impact on health outcomes
for individual cancer patients, their
carers and the community as a whole.
We are calling on Government to
reconsider the system for access to new
cancer medicines, because the current
process, focussing on cost as opposed
to value, is simply not good enough.
Cancer patients can't wait any longer.
'This Senate Inquiry provides an
opportunity for Australia to learn from
the actions of other countries in order
to develop world leading, innovative
access approaches within our country,
which will ensure ongoing and
sustainable access to new and targeted
cancer medicines,' Mr James said.
wait for new
Australian cancer patients do not have time to wait for access to new
cancer medicines according to Medicines Australia (MA).
Record result is up 54% year
Blackmores has posted net profit after
tax of $18.6m for the half year to 31
December 2014, up 54% year on year.
This follows $12.1m in net profit after
tax for the half year to 31 December
2013, which itself was down 10.7% year
The company said $18.6m was a record
result, on half year sales of $206.4m,
itself up 22% year on year.
CEO Christine Holgate said all regions
and brands in the group delivered
strong year on year growth, positioning
the company well for the second half of
the financial year.
She said Blackmores was delivering
against its four strategic priorities
which included growing the Australian
business and investing in growth in Asia.
Blackmores' Australian sales were up
29%, boosted by stronger pharmacy
sales and a growing demand from
Chinese customers, she said.
Links Archive Australian Pharmacist March 2015 Australian Pharmacist May 2015 Navigation Previous Page Next Page